NASDAQ:BFRA

Biofrontera (BFRA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.51
$2.78
50-Day Range
$2.50
$3.60
52-Week Range
$2.09
$7.54
Volume
7,263 shs
Average Volume
27,512 shs
Market Capitalization
$73.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BFRA stock logo

About Biofrontera Stock (NASDAQ:BFRA)

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

BFRA Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Biofrontera plant eine Finanzierungsrunde
Q4 2023 Biofrontera Inc Earnings Call
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Biofrontera Inc BFRI
What's Going On With Biofrontera Stock?
Biofrontera Shares Rise on Maruho Settlement
Biofrontera AG B8F
See More Headlines
Receive BFRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/24/2021
Today
5/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BFRA
Employees
138
Year Founded
N/A

Profitability

Net Income
$-14,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$36.19 million
Book Value
$0.35 per share

Miscellaneous

Free Float
N/A
Market Cap
$73.73 million
Optionable
Not Optionable
Beta
1.02
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

BFRA Stock Analysis - Frequently Asked Questions

How were Biofrontera's earnings last quarter?

Biofrontera AG (NASDAQ:BFRA) issued its quarterly earnings results on Wednesday, November, 24th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. The company earned $6.34 million during the quarter. Biofrontera had a negative trailing twelve-month return on equity of 93.31% and a negative net margin of 59.44%.

What other stocks do shareholders of Biofrontera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biofrontera investors own include AbbVie (ABBV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Adaptimmune Therapeutics (ADAP), GW Pharmaceuticals (GWPH), Pfizer (PFE), Alnylam Pharmaceuticals (ALNY) and Ascendis Pharma A/S (ASND).

When did Biofrontera IPO?

Biofrontera (BFRA) raised $18 million in an IPO on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark acted as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

This page (NASDAQ:BFRA) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners